Globeflex Capital L P decreased its holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 7.0% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 81,977 shares of the medical instruments supplier’s stock after selling 6,200 shares during the quarter. LeMaitre Vascular makes up approximately 0.6% of Globeflex Capital L P’s holdings, making the stock its 18th largest holding. Globeflex Capital L P owned 0.44% of LeMaitre Vascular worth $2,559,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. Russell Investments Group Ltd. grew its holdings in LeMaitre Vascular by 5.6% in the 2nd quarter. Russell Investments Group Ltd. now owns 158,761 shares of the medical instruments supplier’s stock valued at $4,956,000 after buying an additional 8,348 shares during the period. Federated Investors Inc. PA grew its holdings in LeMaitre Vascular by 3.2% in the 2nd quarter. Federated Investors Inc. PA now owns 168,678 shares of the medical instruments supplier’s stock valued at $5,266,000 after buying an additional 5,173 shares during the period. Ameriprise Financial Inc. grew its holdings in LeMaitre Vascular by 52.3% in the 1st quarter. Ameriprise Financial Inc. now owns 201,508 shares of the medical instruments supplier’s stock valued at $4,963,000 after buying an additional 69,186 shares during the period. Bank of New York Mellon Corp grew its holdings in LeMaitre Vascular by 1.6% in the 1st quarter. Bank of New York Mellon Corp now owns 88,552 shares of the medical instruments supplier’s stock valued at $2,181,000 after buying an additional 1,408 shares during the period. Finally, Thomson Horstmann & Bryant Inc. grew its holdings in LeMaitre Vascular by 1.8% in the 2nd quarter. Thomson Horstmann & Bryant Inc. now owns 365,977 shares of the medical instruments supplier’s stock valued at $11,425,000 after buying an additional 6,638 shares during the period. Institutional investors own 66.32% of the company’s stock.

Several research firms have commented on LMAT. BidaskClub cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Wednesday, August 23rd. Zacks Investment Research upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating and set a $38.00 price target for the company in a report on Tuesday, August 1st. Stifel Nicolaus restated a “buy” rating and issued a $32.00 price target (up previously from $29.00) on shares of LeMaitre Vascular in a report on Sunday, July 30th. Benchmark Co. upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Friday, July 28th. Finally, Canaccord Genuity cut LeMaitre Vascular from a “buy” rating to a “hold” rating and set a $28.00 price target for the company. in a report on Monday, July 10th. Four investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $31.60.

Shares of LeMaitre Vascular, Inc. (LMAT) traded down 0.11% during mid-day trading on Friday, hitting $37.25. The stock had a trading volume of 108,493 shares. The company has a 50-day moving average of $35.58 and a 200 day moving average of $29.96. LeMaitre Vascular, Inc. has a one year low of $18.55 and a one year high of $39.29. The firm has a market cap of $708.57 million, a price-to-earnings ratio of 53.21 and a beta of 0.67.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Thursday, July 27th. The medical instruments supplier reported $0.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.17 by $0.06. The firm had revenue of $25.80 million during the quarter, compared to the consensus estimate of $25.42 million. LeMaitre Vascular had a return on equity of 15.02% and a net margin of 14.19%. The business’s revenue for the quarter was up 15.2% on a year-over-year basis. During the same period in the prior year, the business earned $0.14 EPS. On average, equities research analysts forecast that LeMaitre Vascular, Inc. will post $0.80 earnings per share for the current year.

LeMaitre Vascular announced that its board has authorized a share buyback program on Thursday, July 27th that permits the company to buyback $7.50 million in shares. This buyback authorization permits the medical instruments supplier to repurchase up to 1.4% of its shares through open market purchases. Shares buyback programs are generally a sign that the company’s board of directors believes its shares are undervalued.

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 7th. Investors of record on Wednesday, August 23rd were paid a $0.055 dividend. This represents a $0.22 annualized dividend and a yield of 0.59%. The ex-dividend date was Monday, August 21st. LeMaitre Vascular’s dividend payout ratio is currently 31.88%.

In other news, Director Lawrence J. Jasinski sold 6,500 shares of the firm’s stock in a transaction dated Tuesday, August 1st. The stock was sold at an average price of $34.47, for a total transaction of $224,055.00. Following the completion of the sale, the director now directly owns 12,863 shares of the company’s stock, valued at approximately $443,387.61. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Lawrence J. Jasinski sold 2,030 shares of the firm’s stock in a transaction dated Thursday, August 17th. The stock was sold at an average price of $34.23, for a total value of $69,486.90. Following the sale, the director now directly owns 8,333 shares of the company’s stock, valued at $285,238.59. The disclosure for this sale can be found here. Over the last three months, insiders sold 373,121 shares of company stock valued at $12,825,992. Company insiders own 23.70% of the company’s stock.

WARNING: “LeMaitre Vascular, Inc. (LMAT) Holdings Reduced by Globeflex Capital L P” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at https://www.thecerbatgem.com/2017/09/23/lemaitre-vascular-inc-lmat-holdings-reduced-by-globeflex-capital-l-p.html.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.

Institutional Ownership by Quarter for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Stock Ratings for LeMaitre Vascular Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular Inc. and related stocks with our FREE daily email newsletter.